Publications:

Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.

Current Oncology (Toronto, Ont.)

Sasamori, Hiroki H; Nakayama, Kentaro K; Razia, Sultana S; Yamashita, Hitomi H; Ishibashi, Tomoka T; Ishikawa, Masako M; Sato, Seiya S; Nakayama, Satoru S; Otsuki, Yoshiro Y; Fujiwaki, Ritsuto R; Ishikawa, Noriyoshi N; Kyo, Satoru S

Publication Date: 2022-05-18

Variant appearance in text: ERBB2: 2356C>G

PubMed Link: 35621684

Variant Present in the following documents:

• Main text
• curroncol-29-00294.pdf

View BVdb publication page

Genomic profile of advanced breast cancer in circulating tumour DNA.

Nature Communications

Kingston, Belinda B; Cutts, Rosalind J RJ; Bye, Hannah H; Beaney, Matthew M; Walsh-Crestani, Giselle G; Hrebien, Sarah S; Swift, Claire C; Kilburn, Lucy S LS; Kernaghan, Sarah S; Moretti, Laura L; Wilkinson, Katie K; Wardley, Andrew M AM; Macpherson, Iain R IR; Baird, Richard D RD; Roylance, Rebecca R; Reis-Filho, Jorge S JS; Hubank, Michael M; Faull, Iris I; Banks, Kimberly C KC; Lanman, Richard B RB; Garcia-Murillas, Isaac I; Bliss, Judith M JM; Ring, Alistair A; Turner, Nicholas C NC

Publication Date: 2021-04-23

Variant appearance in text: HER2: L786V

PubMed Link: 33893289

Variant Present in the following documents:

• Main text

View BVdb publication page

Phase and context shape the function of composite oncogenic mutations.

Nature

Gorelick, Alexander N AN; Sánchez-Rivera, Francisco J FJ; Cai, Yanyan Y; Bielski, Craig M CM; Biederstedt, Evan E; Jonsson, Philip P; Richards, Allison L AL; Vasan, Neil N; Penson, Alexander V AV; Friedman, Noah D ND; Ho, Yu-Jui YJ; Baslan, Timour T; Bandlamudi, Chaitanya C; Scaltriti, Maurizio M; Schultz, Nikolaus N; Lowe, Scott W SW; Reznik, Ed E; Taylor, Barry S BS

Publication Date: 2020-06

Variant appearance in text: ERBB2: L786V

PubMed Link: 32461694

Variant Present in the following documents:

• NIHMS1582596-supplement-1582596_Supp_Tab1-5.xlsx, sheet 2

View BVdb publication page

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Cancer Cell

Robichaux, Jacqulyne P JP; Elamin, Yasir Y YY; Vijayan, R S K RSK; Nilsson, Monique B MB; Hu, Lemei L; He, Junqin J; Zhang, Fahao F; Pisegna, Marlese M; Poteete, Alissa A; Sun, Huiying H; Li, Shuai S; Chen, Ting T; Han, Han H; Negrao, Marcelo Vailati MV; Ahnert, Jordi Rodon JR; Diao, Lixia L; Wang, Jing J; Le, Xiuning X; Meric-Bernstam, Funda F; Routbort, Mark M; Roeck, Brent B; Yang, Zane Z; Raymond, Victoria M VM; Lanman, Richard B RB; Frampton, Garrett M GM; Miller, Vincent A VA; Schrock, Alexa B AB; Albacker, Lee A LA; Wong, Kwok-Kin KK; Cross, Jason B JB; Heymach, John V JV

Publication Date: 2019-10-14

Variant appearance in text: ERBB2: L786V

PubMed Link: 31588020

Variant Present in the following documents:

• Main text

View BVdb publication page